Research platform focused on botanical formulations that support the Endocannabinoid System and promote general wellness
EPI1 Immunotech is building an end-to-end scientific ecosystem that unites discovery, production, and treatment within a single, intelligent framework. Powered by AI powered Clinical Research, a cutting-edge biomedical AI platform, this system transforms research into a continuously learning cycle where every experiment refines the next.
Our integrated infrastructure spans a Dallas research and manufacturing headquarters and a Houston clinical and wellness center, enabling rapid translation from compound design to human study.
Through this ecosystem, EPI1 advances pioneering work in nutritional immunology, post-viral recovery, autoimmune modulation, oncology support, and regenerative medicine—bridging the gap between natural compounds and precision therapeutics.
EPI1's compounds target cytokine balance, mitochondrial function, and endocannabinoid signaling to restore immune homeostasis. Early results show measurable improvement in inflammation and fatigue, guiding expanded blood-assay validation and NIH-supported clinical trials.
In parallel, EPI1's materials-scaling initiative seeks to achieve a 20% annual yield increase through microbial biosynthesis, setting the foundation for sustainable, self-sufficient ingredient production.
Together, these efforts establish EPI1 not just as a biotechnology company, but as a new model for translational science—a living, adaptive network capable of accelerating breakthroughs from the molecular level to real-world health impact.
An adaptive AI knowledge platform that unifies biomedical research, clinical trial data, and molecular analytics into a continuously evolving intelligence network
Every experiment, formulation, and clinical outcome becomes new training data that refines the next discovery cycle. Traditional biotechnology relies on fragmented hand-offs—EPI1's ecosystem enables continuous translation from molecular modeling to therapeutic application in months rather than years.
AI powered Clinical Research employs semantic data modeling and neural-symbolic reasoning to fuse diverse datasets—literature, omics data, cytokine assays, microbiome profiles, and patient outcomes—into a single knowledge graph.
A Living "Alexandria of Immunology"
An expanding body of knowledge that anticipates disease patterns and accelerates the design of interventions
Four interconnected areas of scientific focus driving breakthrough therapies
EPI1 studies how nutrients, phytochemicals, and endocannabinoid ligands restore immune balance through cytokine modulation and neuro-immune signaling.
The work targets chronic inflammation, post-viral fatigue, and dysbiosis, using molecular pathways such as CB1/CB2, TRPV1, and FAAH as therapeutic levers.
Long COVID and autoimmune diseases now represent a combined global market exceeding $130 billion USD.
EPI1's platform identifies shared immunopathology—hypercytokinemia, mitochondrial impairment, and microvascular dysfunction—and develops safe, multi-target interventions to restore homeostasis without immune suppression.
Global oncology spending rose from $223 billion USD in 2023 and is projected to reach $409 billion USD by 2028.
EPI1's compounds help mitigate chemotherapy-related fatigue, neuropathy, and inflammation by stabilizing cytokine balance and endothelial health, serving as an adjunctive resilience therapy for cancer patients.
EPI1's regenerative program enhances stem-cell differentiation and survival through immunomodulatory microenvironments.
Integration of stem-cell data within Alexandria enables rapid transfer of insight between regenerative and immune research, creating synergistic breakthroughs across therapeutic domains.
Strategic phased approach prioritized by global health impact and speed to market
EPI1's research program is prioritized in four stages based on:
Addressing urgent medical needs
Likelihood of FDA pathway
Additional studies needed
Timeline to commercialization
We will pursue grant funding through NIH translational-research programs and complementary public-private initiatives to support these phases.
EPI1 is establishing formal collaborations with PRCCI, UAGM, and Inteco in Puerto Rico to conduct early-phase and post-market clinical studies.
UAGM's School of Naturopathy and its multiple lab facilities provide access to animal, toxicology, and chromatography testing. This partnership structure allows EPI1 to generate high-quality data under FDA-aligned oversight while maintaining cost efficiency and rapid iteration of formulations.
Regulatory compliance built-in
Maximizing research value
Fast formulation optimization
Developing botanical formulations guided by research into wellness support and natural balance